

Page 4, please amend the last paragraph lines  
22-28 through page 5 lines 1-20 as follows:

C<sub>2</sub>

The Langerhans cell migration inhibitor of the present invention is generally used in the form of a pharmaceutical composition comprising active vitamin D in combination with a pharmaceutical carrier and formulated as a solution or ointment for topical administration. The compositions are preferably formulated as an ophthalmic liniment, especially an ophthalmic solution. Examples of carriers suitable for these formulations include, but are not limited to, water, ethanol, ethylene glycol, propylene glycol, polyvinyl alcohol, polyvinyl pyrrolidone, gum arabic, calcium phosphate, alginate, gum tragacanth, gelatin, methylcellulose, talc, magnesium stearate, hyaluronic acid, chondroitin sulfate, collagen, fat and mineral oils. In addition to these carriers, the pharmaceutical compositions of the present invention may contain other additives such as a stabilizer, preservative, isotonizing agent, pH-modifier, antioxidant and colorant. Examples of the stabilizer include, but are not limited to, sodium bisulfite, glycerin, sodium edetate, sodium citrate and butyl hydroxyanisole. Example of the preservative include, but are not limited to, benzalkonium chloride. Example of the isotonizing agent include, but are not limited to, sodium chloride,